Information Provided By: 
Fly News Breaks for September 15, 2016
BLUE
Sep 15, 2016 | 06:26 EDT
Goldman analyst Salveen Richter added bluebird to the Conviction Buy List ahead of numerous catalysts and a value inflection point. Richter expects Gen2 data versus Gen1 data at the October 13 R&D day to show substantial efficacy improvements, which is underappreciated by the Street, a full LentiGlobin update at ASH scheduled for December 3-6, the unveiling of the CAR T/gene editing programs, and two pivotal readouts in mid-17 that will result in a transition to commercial focus. The analyst has a $135 price target on bluebird shares.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
